Hexestrol diphosphate | 24809-02-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: Hexestrol diphosphate
• 英文别名: [4-[(3S,4R)-4-(4-phosphonooxyphenyl)hexan-3-yl]phenyl] dihydrogen phosphate
• CAS: 24809-02-7
• 化学式: C₁₈H₂₄O₈P₂
• 分子量: 430.3
• InChiKey: JBDIWCWZUDNWTL-HDICACEKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Method for producing microcapsule
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0190833A2

  公开（公告）日：1986-08-13

  Microcapsules are advantageously produced with a high take-up of a water-soluble drug by preparing a W/O emulsion composed of a water-soluble drug-containing solution as the inner aqueous phase and a polymer-containing solution as the oil phase, dispersing said emulsion in an aqueous phase and subjecting the resulting W/O/W emulsion to an in-water drying, wherein the viscosity of the W/0 emulsion used in preparing the W/O/W emulsion is adjusted to about 150 to about 10,000 centipoises.

  制备由水溶性药物溶液（作为内水相）和聚合物溶液（作为油相）组成的 W/O 乳化液，将所述乳液分散在水相中，然后将所得 W/O/W 乳化液进行水内干燥，就能生产出具有高水溶性药物吸收率的微胶囊，其中用于制备 W/O/W 乳化液的 W/0 乳化液的粘度调整为约 150 至约 10,000 厘泊。
• Controlled Drug-Release Composition and Drug-Releasable Medical Device
  申请人：Mochizuki Akira

  公开号：US20090048667A1

  公开（公告）日：2009-02-19

  A drug-releasable medical device contains a controlled drug-release composition comprising 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a lipid-soluble, low molecular weight release auxiliary agent and 1 to 70 parts by weight of a drug. When the composition is applied on a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, the medical device is provided with a drug release function. Argatroban or sarpogrelate hydrochloride or both of them are gradually released from the surface of a stent for treating coronary artery stenosis, for example. In order to exhibit a sustained-release function for a desired period of time, the drug to be gradually released is carried in a polymeric material coated on a surface of a metal forming the stent or in a porous stent substrate.
• Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
  申请人：Biocopea Limited

  公开号：US20160008376A1

  公开（公告）日：2016-01-14

  The present specification discloses compositions comprising at least one therapeutic compound capable of modulating a level and/or activity of a hormone and methods and uses for treating a gender-biased immune disorder using such compositions.
• US4954298A
  申请人：——

  公开号：US4954298A

  公开（公告）日：1990-09-04
• US5330767A
  申请人：——

  公开号：US5330767A

  公开（公告）日：1994-07-19